logo
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm

New York, New York--(Newsfile Corp. - February 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the 'Offering Documents') issued in connection with Neumora's September 2023 initial public offering (the 'IPO'), of the important April 7, 2025 lead plaintiff deadline.
SO WHAT: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Neumora class action, go to https://rosenlegal.com/submit-form/?case_id=34655 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, the Offering Documents contained false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ('MDD') to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Neumora class action, go to https://rosenlegal.com/submit-form/?case_id=34655 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NVIDIA Stockholder Meeting Set for June 25; Individuals Can Participate Online
NVIDIA Stockholder Meeting Set for June 25; Individuals Can Participate Online

Yahoo

time19 minutes ago

  • Yahoo

NVIDIA Stockholder Meeting Set for June 25; Individuals Can Participate Online

SANTA CLARA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- NVIDIA today announced it will hold its 2025 Annual Meeting of Stockholders online on Wednesday, June 25, at 9 a.m. PT. The meeting will take place virtually at Stockholders will need their control number included in their notice or proxy card to access the meeting and may vote and submit questions while attending the meeting. Non-stockholders are welcome to attend by going to the above link and registering under 'Guest Login.' The matters to be voted on at the meeting are set forth in the company's proxy statement filed on May 13, 2025, with the U.S. Securities and Exchange Commission. The proxy statement is available at A replay of the 2025 annual meeting webcast will be available until June 24, 2026, at About NVIDIANVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing. For further information, contact: NVIDIA Investor Relationsir@ NVIDIA Corporate Communicationspress@ © 2025 NVIDIA Corporation. All rights reserved. NVIDIA and the NVIDIA logo are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

PreveCeutical Announces Non-Brokered Private Placement
PreveCeutical Announces Non-Brokered Private Placement

Yahoo

time21 minutes ago

  • Yahoo

PreveCeutical Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 15,000,000 units in the capital of the Company (the "Units") at a price of $0.05 per Unit for gross proceeds of up to $750,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.08 per Warrant Share for a period of 24 months from the closing of the Offering (the "Closing"); provided that the expiry of the Warrants can be accelerated if the closing price of the Company's common shares on the Canadian Securities Exchange (the "CSE") is $0.10 or greater for a minimum of ten consecutive trading days, and a notice of acceleration is provided in accordance with the terms of the Warrants. Finder's fees may be paid. The Company intends to use the aggregate gross proceeds from the sale of the Offering to pay outstanding payables, for operating expenses and for general working capital purposes. All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after the Closing. Completion of the Offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE. The securities issued under the Offering will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook. On behalf of the Board of Directors of PreveCeutical, Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@ Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the proposed Offering, the expectations of management regarding the use of proceeds of the Offering, closing conditions for the Offering, the expiry of hold periods for securities distributed pursuant to the Offering and other statements regarding the company's proposed business plans. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that: the Company may not complete the Offering on terms favorable to the Company or at all; the proceeds of the Offering may not be used as stated in this news release; the Company may be unable to satisfy all of the conditions to the Closing; and those additional risks set out in the Company's public documents filed on SEDAR+ at Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pride at Work Canada Closes the Market
Pride at Work Canada Closes the Market

Yahoo

time21 minutes ago

  • Yahoo

Pride at Work Canada Closes the Market

Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - Colin Druhan, Executive Director, Pride at Work Canada/Fierté au travail Canada ("Pride" or "Pride at Work Canada") his team, and a selected group of Community and Proud Partners, joined Dani Cohen, Head of Talent and Organizational Development, Human Resources, TMX Group, to close the market to celebrate Pride Month. Cannot view this video? Visit: This meaningful event reflects the growing recognition that uplifting 2SLGBTQIA+ human rights in the workplace is not just a matter of equity, but a strategic business imperative. By championing welcoming cultures, employers empower current and future talent to thrive authentically. With a national network of over 250 Proud Partners, Pride at Work Canada demonstrates that organizations across sectors are not only celebrating Pride, but actively working year-round to build safer, more inclusive, and equitable workplaces for all. The vision that Pride at Work Canada shares with their employer members is a Canada where every individual can achieve their full potential at work, regardless of gender expression, gender identity, and sexual orientation. MEDIA CONTACT:Andrew PerezMedia Contactandrew@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store